Announcement

Collapse
No announcement yet.

Rindopepimut With Bevacizumab for Patients With Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Rindopepimut With Bevacizumab for Patients With Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

    Rindopepimut With Bevacizumab for Patients With Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

  • #2
    Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

    This is a difficult study to interpret. There have been many trials of this vaccine. The early trials looked fantastic and this one looks pretty good. However, the largest randomized phase 3 "ACT 4" trial showed no improvement in overall survival. My thoughts are that the vaccine helps some people, with minimal side effects. Not enough to be used by itself but might be part of the ultimate cocktail. Treatments like this would be perfect candidates for the conditional approval pathway we are working on.

    Comment

    Working...
    X